Efficacy and safety of intravitreal aflibercept treat-and-extent for macular edema in central retinal vein occlusion: the centera study
International Journal of Development Research
Efficacy and safety of intravitreal aflibercept treat-and-extent for macular edema in central retinal vein occlusion: the centera study
Received 20th April, 2021; Received in revised form 19th May, 2021; Accepted 03rd June, 2021; Published online 28th July, 2021
Copyright © 2021, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled: “Efficacy and safety of intravitreal aflibercept treat-and-extend for macular edema in central retinal vein occlusion: Centera study” published in Am J Ophthalmol by Korobelnik 2021; 227(July): 106-115, which assessed the efficacy and safety of intravitreal aflibercept administered using a treat-and-extend dosing regimen in 160 treatment-naïve patients with macular edema secondary to central retinal vein occlusion. The authors concluded that intravitreal aflibercept administered in a treat-and-extend treatment paradigm improved functional and anatomic outcomes in patients with macular edema resulting from central retinal vein occlusion during a 76 week follow-up period. However, the validation, extrapolation, and generalizabilty of these findings can be made only by regression analyses including all the missing data referred to above by us in addition to the baseline characteristics already assessed in this study, serving to identify the potential prognosticators influencing the efficacy and safety of intravitreal aflibercept using a treat-and extend approach for macular edema due to central retinal vein occlusion.
